JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M103397200 on July 26, 2001

J. Biol. Chem., Vol. 276, Issue 39, 36295-36302, September 28, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/39/36295    most recent
M103397200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frank, G.
Right arrow Articles by Shen, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frank, G.
Right arrow Articles by Shen, B.

Stimulation of Eukaryotic Flap Endonuclease-1 Activities by Proliferating Cell Nuclear Antigen (PCNA) Is Independent of Its in Vitro Interaction via a Consensus PCNA Binding Region*

Geoffrey FrankDagger, Junzhuan QiuDagger, Li Zheng, and Binghui Shen§

From the Department of Cell and Tumor Biology, City of Hope National Medical Center, Duarte, California 91010

Received for publication, April 17, 2001, and in revised form, July 9, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Interaction between human flap endonuclease-1 (hFEN-1) and proliferating cell nuclear antigen (PCNA) represents a good model for interactions between multiple functional proteins involved in DNA metabolic pathways. A region of 9 conserved amino acid residues (residues Gln-337 through Lys-345) in the C terminus of human FEN-1 (hFEN-1) was shown to be responsible for the interaction with PCNA. Our current study indicates that 4 amino acid residues in hFEN-1 (Leu-340, Asp-341, Phe-343, and Phe-344) are critical for human PCNA (hPCNA) interaction. A conserved PCNA interaction motif in various proteins from assorted species has been defined as Q1X2X3(L/I)4X5X6F7(F/Y)8, although our results fail to implicate Q1 (Gln-337 in hFEN-1) as a crucial residue. Surprisingly, all hFEN-1 mutants, including L340A, D341A, F343A, and F344A, retained hPCNA-mediated stimulation of both exo- and flap endonuclease activities. Furthermore, our in vitro assay showed that hPCNA failed to bind to the scRad27 (yeast homolog of FEN-1) nuclease. However, its nuclease activities were significantly enhanced in the presence of hPCNA. Four additional Saccharomyces cerevisiae scRad27 mutants, including multiple alanine mutants and a deletion mutant of the entire PCNA binding region, were constructed to confirm this result. All of these mutants retained PCNA-driven nuclease activity stimulation. We therefore conclude that stimulation of eukaryotic hFEN-1 nuclease activities by PCNA is independent of its in vitro interaction via the PCNA binding region.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

DNA replication and repair are critical for maintaining genome stability. These processes are in part dependent on the activities of an emerging family of structure-specific endonucleases. These enzymes, typified by eukaryotic flap endonuclease-1 (FEN-1),1 are substrate structure-specific and multifunctional (1-3). They possess both flap-specific endonuclease and nick-specific exonuclease (ribonuclease) activities and interact with proliferating cell nuclear antigen (PCNA) as well as other proteins (3-5). This unique substrate-specific nature is based on structural elements that have been observed in the three-dimensional structures of prokaryotic FEN-1 homologues (6-10). The N-terminal region and the region located in between the two conserved nuclease motifs three-dimensionally form an arch, thus creating a hole in the middle of the protein. The dimensions of the hole only allow single-stranded DNA, but not double-stranded DNA, to thread through. The presence of positively charged and bulky residues in the helices of the arch region may directly interact with DNA substrate. Other structural features, such as the H3TH motif, dynamically hold the double-stranded portion of the flap substrate (7). Therefore, hFEN-1 nuclease is able to recognize the ends of free 5' single strand DNA and thread it through the hole, resulting in cleavage at the junction between the single-stranded and double-stranded DNA portions of the substrate (11). At the cellular level, hFEN-1 nuclease is able to localize into nuclei in a cell cycle-dependent and DNA damage-inducible manner (12). To date, nine different proteins involved in DNA metabolic pathways have been reported to interact with hFEN-1 nuclease. They include PCNA, APE-1, Dna2 helicase, RPA, replication factor C (RF-C), pol alpha , pol beta , pol epsilon , and type II DNA topisomerase (13-18). All of these proteins are essentially involved in two different general cellular processes, namely DNA replication and DNA base damage repair, which is consistent with the dual roles of hFEN-1 in DNA replication and repair.

Among these FEN-1 interactive proteins, PCNA has been studied intensively. It was originally identified as a processivity factor for DNA polymerase delta  (19, 20) and epsilon  (21). PCNA functions as a homotrimer with a subunit molecular mass of 31 kDa for hPCNA (29 kDa for scPCNA) and is highly conserved from yeast to mammalian cells (22). Besides its roles in DNA replication, PCNA has been shown to be a critical regulating factor through its interaction with various important proteins involved in repair and cell cycle control including xeroderma pigmentosum group G (XPG) nuclease (23), DNA (cytosine-5) methyltransferase (MCMT) (24), p21 (25), MSH2 (26), and MSH3 (27). In vitro experiments have revealed that PCNA can bind to these proteins and can also stimulate specific enzymatic activities. Under native conditions PCNA exists as a monomer and must homotrimerize in order for it to encircle DNA. PCNA can trimerize around double-stranded DNA by simple diffusion or trimerize first and slide onto DNA provided there are free ends. However, it is most efficiently loaded as a trimer onto closed circular double-stranded DNA by the accessory protein RF-C in an ATP-dependent process (28, 29). The crystal structure of scPCNA shows that the trimer forms a closed ring with appropriate dimensions and electrostatic properties that enable it to encircle double-stranded DNA and to interact with DNA using nonspecific contacts (30). Processivity during DNA synthesis is achieved by a direct protein-protein interaction between PCNA and polymerase delta  as PCNA tethers the DNA polymerase at the primer terminus. Once loaded onto DNA, RF-C dissociates from the DNA template while PCNA remains encircled around the template in order to tether DNA polymerase delta  to DNA, thus enabling it to participate in both leading and lagging strand DNA synthesis. After PCNA is loaded onto DNA, it is able to freely slide on the DNA template in either direction (29).

The Lieber and Burgers group was the first to report that human and yeast PCNA (hPCNA and scPCNA) interacts with the hFEN-1 and scRad27 nucleases and stimulates their activities, respectively (5, 15). Using the yeast two-hybrid system, Li et al. (15) demonstrated that yeast scRad27 directly binds to scPCNA. This specific interaction was further confirmed by affinity chromatography using scPCNA beads and yeast cell crude extract containing scRad27. Through protein-protein interactions, PCNA focuses hFEN-1 on a branched DNA substrate (flap endonuclease substrate) and on a nicked DNA substrate (exonuclease substrate), thereby stimulating its activity 10-50-fold depending on the salt concentrations used in the reactions (5). The exact mechanism of stimulation remains unclear. Recent in vitro studies suggest that PCNA stimulates nuclease activities by lowering the Km value of hFEN-1 for DNA substrates (31). Additionally, there are two regions in PCNA that have been shown to be potential binding sites for hFEN-1. The first of these regions is located in the interdomain connector loop (IDCL) of PCNA (32), and the second sequence is found near the C terminus of PCNA (21, 33). FEN-1 is critical during Okazaki fragment maturation on the lagging strand. FEN-1 helps remove RNA primers in a process during which it either functions alone as an endonuclease or as an exonuclease in cooperation with RNase H (34, 35). In vitro stimulation of hFEN-1 endonuclease and exonuclease activities by PCNA suggests that this phenomenon may be important during DNA replication in vivo. In addition, the interaction of FEN-1 and PCNA has also been shown to be important for DNA repair, specifically for the removal of oxidative base damage via long patch base excision repair (36-38). The absence of PCNA in reconstituted in vitro base excision repair reactions containing FEN-1 results in an accumulation of uncleaved or unprocessed damaged DNA intermediates (36). A defective hFEN-1·hPCNA complex may result in inefficient removal of certain types of DNA damage or improper processing of Okazaki fragments, which can produce DNA with secondary structure and eventually result in duplication mutations. The accumulation of DNA damage and increased rates of duplication mutations are examples of primary molecular events that may lead to human cancers and heritable genetic diseases such as colorectal cancers, Huntington's disease, and various ataxias (2, 39, 40).

Via peptide mapping experiments and protein truncation analysis, a conserved region in the C terminus of the hFEN-1 nuclease (337QGRLDDFFK345) has been shown to be the PCNA interaction region (23, 32). When this region is deleted, or, when two critical amino acid residues (Phe-343 and Phe-344) were mutated to alanines, the in vitro binding ability of hFEN-1 to hPCNA was eliminated (36). In this study, we aimed to elucidate details of the structural and functional relationship of this interaction. Comprehensive alanine mutagenesis was performed in the entire proposed PCNA interaction region. Our results demonstrate that 4 amino acid residues in hFEN-1, Leu-340, Asp-341, Phe-343, and Phe-344, were critical for the in vitro interaction with hPCNA. Individual replacement of each of these 4 amino acid residues with alanine resulted in a loss of interaction with hPCNA in vitro. Unexpectedly, all hFEN-1 mutants, including L340A, D341A, F343A, and F344A, retained hPCNA-mediated stimulation properties of both exonuclease and flap endonuclease activities. Further functional interaction analyses of scRad27 nuclease mutants were also carried out. These mutants include multiple alanine mutations of L340/F343/F344, L340/D341/F343/F344, or 337QGRLDDFF344 or a deletion of these 8 amino acid residues (337) in the PCNA-binding region. These alterations resulted in the loss of PCNA binding but retained nuclease activity stimulation. Additionally, human PCNA fails to interact with the scRad27 nuclease, yet it is still able to stimulate the nuclease activities of scRad27. These results suggest that the in vitro interaction of hFEN-1/scRad27 to PCNA and stimulation of nuclease activities are mediated through independent mechanisms.

                              
View this table:
[in this window]
[in a new window]
 
Table I
hFEN-1 and Rad27 mutants constructed in this study and oligos used for mutagenesis

                              
View this table:
[in this window]
[in a new window]
 
Table II
Conserved PCNA binding motif of FEN-1 nucleases and other DNA metabolic proteins


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Site-directed Mutagenesis of FEN-1 and RAD27-- All mutant proteins created for this study were prepared using the QuikChangeTM site-directed mutagenesis kit from Stratagene (La Jolla, CA). A pair of mutagenic primers for each mutant was synthesized at the City of Hope DNA/RNA/peptide synthesis core facility. All together, 12 mutants of human FEN-1 and yeast Rad27 were made for this study. Mutations and corresponding oligo sequences are listed in Table I for clarity. Mutagenesis reactions contain 50 ng of template pET28 derived plasmids harboring the wild type FEN-1 (41), RAD27 (34), or the 3A rad27 mutant (this study) gene sequence, 125 ng of each primer, a 10 mM dNTP mix, and 1 µl (2.5 units/µl) of Pfu polymerase, and then subjected to thermal cycling. Polymerase chain reactions were carried out with the following parameters: 95 °C for 30 s (one cycle only), followed by 16 cycles of 95 °C for 30 s, 55 °C for 1 min, and 68 °C for 14 min according to the manufacturer's instructions (Stratagene, La Jolla, CA). After thermal cycling, 10 units of DpnI restriction enzyme was added to each reaction to digest parental template DNA. DpnI-digested samples were then transformed into Escherichia coli DH5alpha -competent cells. Individual colonies were picked. Plasmid DNA was purified using a minipreparation kit (Qiagen, Valencia, CA). DNA sequence analysis was performed at the City of Hope DNA sequencing facility to verify the alterations. After confirming the mutation, the desired plasmid DNA was then transformed into E. coli BL21(DE3) cells for protein overexpression.

Protein Overexpression and Purification-- Protocols for protein overexpression and purification have been described in our previous work (34, 42). After transformed E. coli BL21(DE3) cells were amplified, protein expression was induced by isopropyl-beta -D-thiogalactopyranoside, cells were harvested, soluble FEN-1 and Rad27 wild type and mutant proteins were extracted in a Tris-based buffer (20 mM Tris, pH 7.9, 150 mM NaCl) and were bound to a 5-ml Ni2+ chelating column, which is facilitated by a fast protein liquid chromatography system (Amersham Pharmacia Biotech). The column was then washed with 40 mM imidazole, and specifically bound protein was eluted over a gradient spanning a concentration range from 40 to 350 mM imidazole over a total volume of 50 ml. Fractions were collected in 2-ml aliquots for a total of 25 fractions, and appropriate fractions were analyzed using SDS-PAGE to determine which ones contained purified protein. Fractions containing the desired protein were pooled and then exchanged into a buffer of 20 mM Tris-Cl, pH 7.9, 150 mM NaCl using a de-salting column (Amersham Pharmacia Biotech). Protein concentration was determined using the Bio-Rad (Bradford) protein assay reagents, and then an equal volume of glycerol was added to each protein sample for storage at -20 °C.

FEN-1·PCNA Binding Assays-- A binding assay protocol was designed based on the published methods developed by Gary et al. (36) and Stucki et al. (43). Briefly, cells harboring the wild type or mutant His-tagged human FEN-1 or yeast Rad27 protein, and non-histidine-tagged human or yeast PCNAs were grown, induced, and harvested as described previously (34, 42). Binding reactions contain 150 µl of crude cell extracts of the appropriate FEN-1 or Rad27 protein and the appropriate PCNA protein, 150 µl of a 50% slurry of beads charged with 50 mM NiSO4 and 450 µl of Tris-based buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl). To facilitate the protein-protein interaction, samples were gently shaken at 4 °C for 90 min. Beads were collected by gravity and then washed four times with wash buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 60 mM imidazole). Following the final wash, beads were resuspended in 75 µl of 2× protein sample loading buffer (100 mM Tris, pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.2% bromphenol blue, 20% glycerol), boiled, the supernatant was collected, followed by analysis using SDS-PAGE. The gel was stained with Coomassie Blue R250 for visualization of proteins that were bound to the beads. A FEN-1·PCNA complex was confirmed by visualizing the presence of both a protein band for hFEN-1 (~42 kDa) or scRad27 (~42 kDa) and a band for human or yeast PCNA (~31 and 29 kDa, respectively) on the gel.

DNA Substrate Preparation and PCNA-dependent FEN-1 Nuclease Activity Assays-- The following four oligos were synthesized at the City Of Hope DNA/RNA/peptide synthesis facility and were used to prepare the flap endonuclease and exonuclease substrates: Flap-G1 (5'-GATGTCAAGCAGTCCTAACTTTGAGGCAGAGTCC-3'), Temp-1G (5'-GGACTCTGCCTCAAGACGGTAGTCAACGTG-3'), Prim-3B (5'-CACGTTGACTACCGTC-3'), and Exo-3PT (5'-TTGAGGCAGAGTCC-3'). Flap-G1 (labeled oligo of the flap substrate) and Exo-3PT (labeled oligo of the exonuclease substrate) were 5' end-phosphorylated by incubating 40 pmol of oligo with 10 µCi of [gamma -32P]ATP and 1 µl (10 units/µl) of polynucleotide kinase at 37 °C for 60 min. Polynucleotide kinase enzyme was inactivated by heating the sample at 72 °C for 10 min. 80 pmol each of the Temp-3B and Prim-1G oligos were then added to the labeled oligos, respectively. The samples were incubated at 70 °C for 5 min, followed by slow cooling to 25 °C to allow the oligos to slowly anneal and form the flap endonuclease and exonuclease substrates as shown in Fig. 2 (A and B). Substrates were precipitated at -20 °C overnight after adding 20 µl of 3 M NaOAc and 1 ml of 100% ethanol. Substrates were collected by centrifugation, washed once with 70% ethanol, and resuspended in sterile water.

For PCNA-independent assays, reactions were carried out with 120 fmol of hFEN-1 or scRad27 and 500 fmol of flap or exonuclease substrate in 13 µl of 50 mM Tris (pH 8.0), 10 mM MgCl2, and 100 µg/ml BSA. For PCNA-dependent flap endonuclease activity stimulation assays, 120 fmol of the appropriate FEN-1 or Rad27 was mixed with 2.6 µl of 5× reaction buffer with high salt concentration (250 mM Tris-Cl, pH 8.0, 50 mM MgCl2, 375 mM NaCl), 500 fmol of flap substrate, and 3,000 fmol of human or yeast PCNA. Each reaction was then brought to a total volume of 13 µl with water. As for the PCNA-dependent exonuclease activity stimulation assays, 240 fmol of FEN-1 or Rad27 protein, 3,000 fmol of human or yeast PCNA, and 500 fmol of exonuclease substrate were mixed with 2.6 µl of 5× reaction buffer with low salt concentration (250 mM Tris-Cl, pH 8.0, 50 mM MgCl2, and 125 mM NaCl). Each reaction was then brought to a total volume of 13 µl with water. All reactions were incubated at 30 °C for 15 min and terminated by adding an equal volume of stop solution (95% formamide, 20 mM EDTA, 0.05% bromphenol blue, 0.05% xylene cyanol). An aliquot of each reaction was then run on a 15% denaturing PAGE at 1900 V for 1 h. The gel was dried at 70 °C for 50 min, and then visualized by autoradiography.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Identification of hFEN-1 Residues That Are Crucial for hPCNA Binding-- Previous studies have determined some of the amino acid residues in the C-terminal region of hFEN-1 that are crucial for its ability to bind hPCNA (23, 32). Our current study aimed to comprehensively analyze each amino acid residue in the consensus PCNA binding region of hFEN-1 to determine which residues were necessary for binding. Based on previous findings, we chose to focus on the region of hFEN-1 that includes residues Gln-337 through Lys-345 (3, 12, 32). This region resembles the consensus conserved PCNA binding motif, Q1X2X3(L/I)4X5X6F7(F/Y)8. The residues in bold are conserved in many FEN-1 nuclease homologs and some other PCNA interacting proteins, as shown in Table II, and serve as excellent candidates to begin mutagenic analysis.

We individually mutated 8 of the 9 amino acids in this region to alanine in order to study the PCNA binding role of each residue. The ninth residue, glycine, was excluded in the individual mutational analysis, but was later included in a mutant containing multiple mutations (termed the 8A mutant, see below). Our study indicates that residues Leu-340, Asp-341, Phe-343, and Phe-344 are crucial for the hFEN-1-hPCNA interaction (Fig. 1). Surprisingly, Gln-337 was not important even though this glutamine residue is highly conserved in the PCNA interacting proteins listed in Table II. This result may indicate that the putative PCNA binding motif in the FEN-1/XPG family is actually shorter than proposed and only resembles a motif such as (L/I)1(D/E)2X3(F/W)4F5.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   In vitro interaction abilities of human FEN-1 mutants to human PCNA. Each binding reaction contains crude cell extract from E. coli cells that individually overexpress the indicated histidine-tagged hFEN-1 mutant protein plus crude cell extract from E. coli cells overexpressing non-histidine-tagged hPCNA in the presence of Ni2+-charged beads and binding buffer. Samples were gently mixed, washed, and then proteins bound to Ni2+-charged beads were eluted by boiling in sample buffer and recovering the supernatant. The presence of both hFEN-1 and hPCNA bands in a single lane indicates an in vitro complex of the two proteins. Arrows on the left side indicate the positions and sizes of molecular weight marker proteins. Arrows on the right side indicate the positions of the hFEN-1 and hPCNA proteins.

Nuclease Activity Stimulation of Mutant hFEN-1 Proteins by hPCNA-- It has been shown previously that hFEN-1 endonuclease and exonuclease cleavage activities can be stimulated 10-50-fold by the presence of hPCNA provided that the NaCl concentration is similar to that of physiological conditions (15). This phenomenon occurs because the presence of NaCl inhibits hFEN-1 activity in vitro, and it is the presence of hPCNA that allows hFEN-1 to overcome this inhibition. Each of the eight mutant hFEN-1 proteins created in this study was highly purified in order to analyze in vitro stimulation of endonuclease and exonuclease activities by hPCNA. Logically, one would expect that all mutants that retained binding ability would still be stimulated by hPCNA. Likewise, all mutants that lost their binding ability would also lose their ability to be stimulated. To perform PCNA-dependent nuclease activity assays, we chose to use linearized DNA oligo substrates as shown in Fig. 2 (A and B), which are identical to the substrates used in the original report by Lieber and Burgers (15). Endonuclease and exonuclease activities of each mutant were first tested in the absence of NaCl to confirm that each protein was functional as described under "Materials and Methods" (data not shown). Following this confirmation, we individually assayed the stimulation of both endonuclease and exonuclease cleavage for the eight mutant hFEN-1 proteins as well as the wild type protein. Interestingly, we observed that endonuclease activity of all eight mutants was still stimulated by hPCNA (Fig. 2A). In agreement with these results, we also observed that exonuclease activity of all eight mutants was also stimulated by hPCNA (Fig. 2B). These results were quite unexpected. One observation of importance is that previously created PCNA binding-deficient hFEN-1 and scRad27 mutants have never been assayed for stimulation (e.g. Refs. 36 and 44). Our analysis of the hPCNA-mediated stimulation of hFEN-1 mutant nuclease activity clearly demonstrates that amino acid residues, which were shown to be necessary for binding, were not required for stimulation.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   In vitro human PCNA-mediated stimulation of endonuclease and exonuclease activities of mutant hFEN-1 proteins. A, flap endonuclease cleavage stimulation of the wild type hFEN-1 and 8 mutant hFEN-1 proteins by hPCNA. Each protein was assayed in the absence and presence of hPCNA as indicated. Reactions were carried out as described under "Materials and Methods." Uncleaved substrate and the 19- and 21-nucleotide cleavage products are labeled to the left side. Above the panel is a pictorial representation of the flap endonuclease substrate used for all PCNA-dependent nuclease activity assays; the asterisk indicates the location of the 32P-labeled 5' end phosphate group. The arrows indicate the cleavage sites that produce the 19-, 20-, and 21-nucleotide cleavage products. The bottom panel is the -fold differences between flap endonuclease activities with or without the presence of hPCNA. B, exonuclease cleavage stimulation of the wild type hFEN-1 and 8 mutant hFEN-1 proteins by hPCNA. Each protein was assayed in the absence and presence of hPCNA as indicated. Reactions were carried out as described under "Materials and Methods." Uncleaved substrate and the 1-, 2-, and 3-nucleotide cleavage products are labeled to the left side. Above the panel is a pictorial representation of the exonuclease substrate used for all PCNA-dependent nuclease activity assays; the asterisk indicates the location of the 32P-labeled 5' end phosphate group. The arrows indicate the cleavage sites that produce the 1-, 2-, and 3-nucleotide cleavage products. The bottom panel is the -fold differences between exonuclease activities with or without the presence of PCNA.

hFEN-1 or Rad27 Binding and Activity Stimulation by Human and Yeast PCNA-- When the Lieber and Burgers' group first demonstrated the intraspecies interaction and stimulation between hFEN-1/scRad27 and its respective PCNA, they also reported that the interspecies stimulation of hFEN-1 by scPCNA was poor (5). This observation was then utilized to explain genetic data obtained in rad27 mutant complementation experiments by hFEN-1(44, 45). Our current work was designed to determine if the human and S. cerevisiae PCNA proteins (hPCNA and scPCNA, respectively) were able to bind to hFEN-1 or scRad27 and stimulate the nuclease activities intra- and interspecifically. First, we tested the ability of both PCNAs to bind to hFEN-1 or scRad27. Fig. 3 shows the interspecific binding properties of hFEN-1 and scRad27 to human and yeast PCNA. The data indicate that hFEN-1 binds to hPCNA and scPCNA with no apparent qualitative difference. scRad27 binds only to scPCNA under the same reaction conditions, whereas it failed to bind to hPCNA. This indicates that the regions of hPCNA and scPCNA where hFEN-1 binds are similar enough that hFEN-1 is unable to discriminate between the two sites. On the other hand, the results in Fig. 3 also show that scRad27 is able to bind scPCNA, but not hPCNA. This may illustrate subtle differences of hFEN-1 and scRad27 binding to PCNA from different species.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Intraspecies and interspecies binding abilities of hFEN-1 and scRad27 to human and yeast PCNAs. Binding experiments were performed as described previously using histidine-tagged hFEN-1 or scRad27 crude cell extract, non-histidine-tagged hPCNA or scPCNA crude cell extract, Ni2+-charged beads, and binding buffer followed by analysis on SDS-PAGE. Arrows on the left side indicate the positions and sizes of molecular weight marker proteins. Arrows on the right side indicate the positions of the hFEN-1 or scRad27 protein and the human or yeast PCNA proteins.

Additionally, using hPCNA and scPCNA, we assayed the stimulation of flap endonuclease and exonuclease activities of hFEN-1 and scRad27, and we clearly demonstrated that nuclease activities are stimulated in the presence of hPCNA or scPCNA (Fig. 4). Even though the interspecific binding abilities of hFEN-1 and scRad27 differ, it is clear that both proteins are stimulated by the corresponding interspecific PCNA to a similar degree. Again, these data further confirm the fact that deficiency of our hFEN-1 mutants in hPCNA binding does not necessarily correlate with stimulation of nuclease activities.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 4.   Intraspecies and interspecies PCNA-mediated stimulation of endonuclease and exonuclease activities of hFEN-1 and scRad27. The left side shows hPCNA intraspecies- and interspecies-mediated stimulation of the endonuclease and exonuclease activities of hFEN-1 and scRad27. The right side shows scPCNA interspecies- and intraspecies-mediated stimulation of the endonuclease and exonuclease activities of FEN-1 and Rad27. Reactions were carried out as described in Fig. 2 using identical amounts of proteins. Reactions were incubated at 30 °C for 15 min, quenched, analyzed using 15% PAGE, and visualized by autoradiography. The nucleotide size markers for the endonuclease activity are on the far left side of the panel, and the ones for the exonuclease activity are on the far right side.

Multiple Mutations of Conserved Residues in the PCNA Interaction Motif of Rad27-- Our study has identified the residues critical for hFEN-1 binding to hPCNA, whereas additional data have detailed which residues are important for PCNA binding by other proteins such as ligase I, p21, and MCMT (Table II) (23, 24, 44, 46). Our experiments have also demonstrated that the nuclease activities of single amino acid mutants can still be stimulated by hPCNA. One of the possible explanations is that the presence of other unidentified conserved residues in the PCNA binding region are able to serve as a back-up for stimulation by compensating for single residue mutations. Three residues (LXXFF) in this motif are highly conserved and are essential for binding to PCNA by ligase I, p21, MCMT, hFEN-1, and scRad27 (23, 24, 32, 44, 46, 47). These residues are equivalent to the Leu-340, Phe-343, and Phe-344 residues in hFEN-1 and the Leu-343, Phe-346, and Phe-347 residues in scRad27. We mutagenized these residues in scRad27 to alanine (L343A/F346A/F347A, termed the 3A mutant hereafter). We opted to create this mutant in scRad27 so that it could potentially be used for future in vivo studies in S. cerevisiae. Characterization of the 3A mutant was performed as with the single mutant hFEN-1 proteins. Binding assays of the 3A mutant revealed that this mutant lost its ability to bind to scPCNA (Fig. 5). scPCNA-dependent endonuclease and exonuclease activity assays were also performed. Clearly, the endonuclease and exonuclease activities of the 3A mutant were significantly enhanced by scPCNA (Fig. 6). However, there is an additional conserved amino acid residue, Gln-337 in hFEN-1, which is highly conserved in PCNA-binding proteins, but has been experimentally proven to not be critical for hFEN-1 binding to hPCNA. In order to clearly demonstrate that the glutamine residue plays no role in binding or stimulation, we constructed a quadruple mutant in scRad27 (Q340A/L343A/F346A/F347A, termed the 4A mutant hereafter). The binding (Fig. 5) and stimulation assays (Fig. 6) of the 4A mutant resulted in data similar to that for the 3A mutant and to the single mutants of hFEN-1. These data indicate that multiple mutations of conserved residues in the putative PCNA binding region do not abolish in vitro PCNA-mediated stimulation of nuclease activities. These properties led us to believe that more comprehensive group mutations, or a deletion of the entire region, may be necessary to create a mutant that cannot have its nuclease activities stimulated.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 5.   Absence of the binding abilities of the 3A, 4A, 8A, and Delta P Rad27 mutants to scPCNA. Binding experiments were performed as described in Fig. 3 using histidine-tagged scRad27 mutant crude cell extracts and non-histidine-tagged scPCNA. Results were analyzed using SDS-PAGE. Arrows on the left side indicate the positions and sizes of molecular weight marker proteins. Arrows on the right side indicate the positions of the scRad27 and scPCNA proteins.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 6.   In vitro scPCNA-mediated stimulation of endonuclease and exonuclease activities of the 3A, 4A, 8A, and Delta P Rad27 mutants. Flap endonuclease activity stimulation (solid gray on left) and exonuclease activity stimulation (striped on right) of the 3A, 4A, and 8A scRad27 mutants by scPCNA. Reactions were carried out as described in Fig. 2 legends. The -fold stimulation values in presence of PCNA were calculated by normalizing the activity in absence of PCNA.

Recently, Stucki et al. (43) constructed a deletion mutant of hFEN-1 (FEN-1Delta P) in order to eliminate 8 residues (Gln-337 through Phe-344) in the PCNA binding motif. Results showed that FEN-1Delta P completely lacked nuclease activity stimulation in hPCNA-dependent assays. The authors concluded that the physical interaction between hFEN-1 and hPCNA is absolutely required for hFEN-1 stimulation. To further elucidate the meaning of our results as well as the conclusion made by Stucki et al. (43), we constructed two additional mutants in scRad27, in which we either changed all 8 residues (Gln-340 through Phe-347) in the hPCNA binding motif to alanines (termed the 8A mutant hereafter), or in which we deleted all 8 residues (termed the Delta P mutant hereafter) in this region.

As expected, both the 8A and Delta P mutants were deficient in their ability to bind to scPCNA (Fig. 5). In contrast to what Stucki et al. (43) has shown, our results revealed that both the 8A and Delta P scRad27 mutants could have their endonuclease and exonuclease activities stimulated in the presence of the scPCNA (Fig. 6). This phenomenon may explain the lack of observable phenotypes of S. cerevisiae cells containing a Rad27 gene harboring the F346A/F347A double mutation (44, 45). The F346A/F347A scRad27 mutant was unable to produce significant phenotypic differences when incorporated in the S. cerevisiae chromosome, probably due to that this double mutant's stimulation properties are similar to that of wild type.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Employing a strategy of individually mutating each of the 8 amino acid residues to alanine residues in the C-terminal putative hPCNA binding motif of hFEN-1 (Table II) allowed us to systematically analyze hFEN-1's ability to bind to hPCNA as well as to determine the effect on the stimulation of its nuclease activities by hPCNA. Our intentions were to precisely determine which residues in hFEN-1 are crucial for binding to hPCNA and then correlate the binding results of individual mutants with their stimulation properties. Our results revealed interesting and novel findings that should expand our overall knowledge of hFEN-1's in vitro binding and stimulation characteristics and may help to further our understanding of previously published in vivo results.

Previous biochemical analysis of PCNA and its interaction with various proteins revealed a conserved sequence in these proteins that is necessary for their ability to bind to PCNA. An 8-amino acid residue consensus PCNA binding motif was derived and is represented by the following sequence: Q1X2X3(L/I)4X5X6F7(F/Y)8. Traditionally, this motif is located at, or near, either the N or C terminus of PCNA-binding proteins. In Table II, boldface letters in the putative PCNA binding motifs of various proteins indicate that residues are highly conserved. Mutational analysis of this motif in hFEN-1 was performed in order to determine the identity of the residues essential for binding to PCNA. Previous analysis of five proteins has partially determined the residues that were essential for PCNA binding by the scRad27, hFEN-1, p21, ligase I, and MCMT proteins (23-25, 32, 44, 46, 47). Residues equivalent to (L/I)4, F7, and (F/Y)8 of the PCNA consensus binding motif are essential for PCNA binding by all five proteins. In our current study, point mutations in the consensus PCNA binding motif of hFEN-1 were created and characterized. Binding analysis of each mutant using crude cell extracts unambiguously showed which residues were essential for hFEN-1 to bind to hPCNA (Fig. 1). In the C-terminal PCNA binding region of hFEN-1, we determined that residues Leu-340, Asp-341, Phe-343, and Phe-344 (equivalent to Leu-343, Asp-344, Phe-346, and Phe-347 in scRad27) were essential for binding. Our experiments further confirmed that the glutamine residue is not essential for the hFEN-1-hPCNA interaction and may not actually be a part of the PCNA binding motif even though it is highly conserved. Instead, aspartate 341, which is conserved in the eukaryotic FEN-1/XPG nuclease family, is a crucial residue in the consensus motif (Table II). Our results suggest that the consensus PCNA binding motif for the FEN-1/XPG family could be better represented as (L/I)1(D/E)2X3(F/W)4F5.

The most interesting and unexpected results obtained in this study involved the analysis of the hPCNA-mediated stimulation of the nuclease activities of hFEN-1 and scRad27 proteins that contained single or multiple mutations in the C-terminal PCNA interaction domain. In order to correlate the experimentally observed binding abilities of mutants with their stimulation properties, all mutant hFEN-1s were analyzed for their hPCNA-mediated flap endonuclease and exonuclease stimulation using in vitro assays (5, 43). We predicted that all mutants that lost binding ability to hPCNA would also lose their ability to be stimulated, and, likewise, mutants that retained binding ability would also retain hPCNA-mediated stimulation of their endo/exonuclease activities. However, all mutants created still retained hPCNA-mediated stimulation of flap endonuclease (Fig. 2A) and exonuclease (Fig. 2B) activities. It was also considered that the presence of PCNA could produce an excluded volume effect similar to the mechanism in which the presence of excess BSA is able to enhance the activity of some restriction enzymes. This possibility was tested using BSA and polyethylene glycol 4000 and observed that this was not the case (data not shown). Alternatively, we also considered the possibility that an undetectable amount of residual binding to hPCNA may exist in any (or all) of the hPCNA binding deficient single mutants because our binding assay may not be sensitive enough to detect residual binding levels. Therefore, we addressed this possibility by mutating multiple conserved residues in combination. The following four mutants of scRad27 were also constructed for this experiment: 1) a triple mutant by changing Leu-343, Phe-346, and Phe-347 all to alanines (3A mutant), 2) a quadruple mutant by changing Gln-340, Leu-343, Phe-346, and Phe-347 all to alanines (4A mutant), 3) a mutant in which residues Gln-340 through Phe-347 were all changed to alanines (8A mutant), and 4) a mutant with a deletion of these 8 residues (Delta P mutant). We assayed binding of these mutants to scPCNA and flap endonuclease and exonuclease activity stimulation by scPCNA. As expected, all of these mutants lost their ability to bind to scPCNA (Fig. 5). All of the scRad27 proteins containing multiple mutations (3A, 4A, and 8A) or a deletion (Delta P) also retained normal nuclease activity stimulation mediated by scPCNA (Fig. 6).

This finding was supported by our further observation that hPCNA was able to stimulate nuclease activities of scRad27 even though it can not bind to scRad27. The original purpose for performing the experiment on interspecific binding and stimulation of hFEN-1 and scRad27 proteins by human or yeast PCNAs was to verify the previous data that scPCNA could not stimulate hFEN-1 nuclease activities (5). Our recent observation shows that hFEN-1 could fully complement scRad27 functions when it was used to rescue rad27 knockout strains (26). This result led us to hypothesize that the scPCNA should be able to bind to hFEN-1 and stimulate its nuclease activities or vice versa. As expected, our present study indicated that the scPCNA could indeed bind to hFEN-1 protein (Fig. 3) and stimulate its nuclease activities (Fig. 4) in vitro. Unexpectedly, we also revealed that hPCNA could stimulates the nuclease activities of scRad27, but was not able to bind to the protein, which support our hypothesis that the binding and stimulation of FEN-1 proteins by PCNA are mediated via independent mechanisms.

The above results led us to consider the possible existence of additional unidentified motif(s) and/or structural elements in RAD27 (or hFEN-1) that could be responsible for the stimulation properties of the wild type and various mutant proteins by PCNA. In a recent report, Gomes and Burgers (48) described that the ability of scRad27 to bind to two distinct regions in scPCNA (the IDCL and C terminus) was regulated by DNA. A yeast IDCL mutant, pcna-79 (IL126, 128AA), failed to interact with scRad27 in solution, but surprisingly, was still very active in stimulating scRad27 nuclease activity. In contrast, a C-terminal mutant, pcna-90 (PK252, 253AA), exhibited wild type binding to scRad27 in solution, yet poorly stimulated the nuclease activities of scRad27. When proteins were individually loaded onto a DNA substrate (resembling our exonuclease substrate) that was coupled to magnetic beads, wild type scPCNA and pcna-79, but not pcna-90, formed a complex with scRad27 and the DNA substrate. These results indicated that the presence of an appropriate DNA substrate dictated the region of PCNA to which Rad27 binds.

The data presented here are contradictory to what Stucki et al. (43) have published recently. Stucki et al. constructed a deletion mutant of hFEN-1 lacking the PCNA interaction motif, which is equivalent to our Delta P scRad27 mutant described here. The sequences of these regions in the two proteins are identical except for 1 residue. They have carried out PCNA interaction and stimulation assays with their mutant and concluded that the PCNA interaction motif is indispensable for stimulation of hFEN-1 activities by hPCNA. Our results using proteins containing single mutant, multiple mutants, or a deletion mutation in the C-terminal region required for in vitro PCNA interaction did not result in significant loss of stimulation. This discrepancy may have resulted from origins of proteins, differences in experimental design, how the mutant proteins were handled, or the removal of an additional amino acid residue, Phe-347, in the yeast enzyme (deletion of 8 residues in scRad27 versus 7 residues in hFEN-1). Among these possibilities, the deletion mutant protein that Stucki et al. and the one that we have constructed may have different folding properties, solubility, and consequently different biochemical functions. We have found that the recombinant scRad27 proteins with multiple point mutations or deletions are not as stable as wild type scRad27 nuclease. The most deleterious case was the 8A mutant, where 8 amino acid residues (337) were converted into a large cluster of alanines. Despite this, we were able to purify the mutant proteins and perform the nuclease activity assays. All of the mutants included in this study have a wild type level of nuclease activities in PCNA-independent assays. Their nuclease activities could be stimulated by PCNA to a level similar to that of the wild type nucleases. Therefore, the stimulation that we observed with these mutants is most likely specific and real. Several mutants, including 3A and 4A, were introduced into rad27 null mutant cells using a yeast expression plasmid (pDB20) and failed to show the significant phenotypes observed in the rad27 null mutants, which is consistent with previous observations (42, 44, 45). This indicates that the activity stimulation instead of the in vitro hFEN-1/hPCNA interaction is responsible for the functional deficiency observed in vivo.

    ACKNOWLEDGEMENTS

We thank John Termini, Tim O'Connor, Adam Bailis, Qing Chai, and other members in the Shen laboratory for their technical assistance and stimulating discussions during the course of this study. We are grateful for the opportunity to collaborate with J. A. Tainer laboratory at the Scripps Research Institute in solving the crystal structure of Pyrococcus furiosus FEN-1 nuclease, which is used as a template for molecular modeling in this study.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA73764 (to B. H. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed to this work equally.

§ To whom correspondence should be addressed: Dept. of Cell and Tumor Biology, City of Hope National Medical Center, 1500 E. Duarte Rd., Duarte, CA 91010. Tel.: 626-301-8879; Fax: 626-301-8972; E-mail: bshen@coh.org.

Published, JBC Papers in Press, July 26, 2001, DOI 10.1074/jbc.M103397200

    ABBREVIATIONS

The abbreviations used are: FEN-1, flap endonuclease-1; hFEN-1, human flap endonuclease-1; PCNA, proliferating cell nuclear antigen; scPCNA, yeast proliferating cell nuclear antigen; hPCNA, human proliferating cell nuclear antigen; pol, polymerase; MCMT, DNA (cytosine-5) methyltransferase; XPG, xeroderma pigmentosum group G; PAGE, polyacrylamide gel electrophoresis; IDCL, interdomain connector loop; RF-C, replication factor C; oligo, oligonucleotide; BSA, bovine serum albumin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Lieber, M. R. (1996) BioEssays 19, 233-240
2. Johnson, R. E., Kovvali, G. K., Prakash, L., and Prakash, S. (1995) Science 269, 238-240
3. Shen, B., Qiu, J., Hosfield, D. J., and Tainer, J. A. (1998) Trends Biochem. Sci. 23, 171-173
4. Bambara, R. A., Murante, R. S., and Henricksen, L. A. (1997) J. Biol. Chem. 272, 4647-4650
5. Wu, X., Li, J., Li, X., Hsieh, C.-L., Burgers, P. M. J., and Lieber, M. R. (1996) Nucleic Acids Res. 24, 2036-2043
6. Ceska, T. A., Sayers, J. R., Stier, G., and Suck, D. (1996) Nature 382, 90-93
7. Hosfield, D. J., Mol, C. D., Shen, B., and Tainer, J. A. (1998) Cell 95, 135-146
8. Hwang, K. Y., Baek, K., Kim, H. Y., and Cho, Y. (1998) Nat. Struct. Biol. 8, 707-713
9. Kim, Y., Eom, S. H., Wang, J., Lee, D. S., Suh, S. W., and Steitz, T. A. (1995) Nature 376, 612-616
10. Meusser, T. C., Nossal, N. G., and Hyde, C. C. (1996) Cell 85, 1101-1112
11. Murante, R. S., Rust, L., and Bambara, R. A. (1995) J. Biol. Chem. 270, 30377-30383
12. Qiu, J., Li, X., Frank, G. A., and Shen, B. (2001) J. Biol. Chem. 276, 4901-4908
13. Biswas, E. E., Zhu, F. X., and Biswas, S. B. (1997) Biochemistry 36, 5955-5962
14. Budd, M. E., and Campbell, J. L. (1997) Mol. Cell. Biol. 17, 2136-2142
15. Li, X., Li, J., Harrington, J., Lieber, M. R., and Burgers, P. M. J. (1995) J. Biol. Chem. 270, 22109-22112
16. Prasad, R., Dianov, G. L., Bohr, V., and Wilson, S. H. (2000) J. Biol. Chem. 275, 4460-4466
17. Siegel, G., Turchi, J. J., Myers, T. W., and Bambara, R. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9377-9381
18. Zhu, F. X., Biswas, E. E., and Biswas, S. B. (1997) Biochemistry 36, 5947-5954
19. Fukuda, K., Morioka, H., Imajou, S., Ikeda, S., Ohtsuka, E., and Tsurimoto, T. (1995) J. Biol. Chem. 270, 22527-22534
20. Zhang, S.-J., Zeng, X.-R., Zhang, P., Toomey, N. L., Chuang, R.-Y., Chang, L.-S., and Lee, M. Y. W. T. (1995) J. Biol. Chem. 270, 7988-7992
21. Eissenberg, J. C., Ayyagari, R., Gomes, X. V., and Burgers, P. M. J. (1997) Mol. Cell. Biol. 17, 6367-6378
22. Kelman, Z., and O'Donnell, M. (1995) Nucleic Acids Res. 23, 3613-3620
23. Gary, R., Ludwig, D. L., Cornelius, H. L., MacInnes, M. A., and Park, M. S. (1997) J. Biol. Chem. 272, 24522-24529
24. Chuang, L. S.-H., Ian, H.-I., Koh, T.-W., Ng, H.-H., Xu, G., and Li, B. F. L. (1997) Science 277, 1996-2000
25. Nakanishi, M., Robetorye, R. S., Pereira-Smith, O. M., and Smith, J. R. (1995) J. Biol. Chem. 270, 17060-17063
26. Chen, C., Merrill, B. J., Lau, P. J., Holm, C., and Kolodner, R. D. (1999) Mol. Cell. Biol. 19, 7801-7815
27. Johnson, R. E., Kovvali, G. K., Guzder, S. N., Amin, N. S., Holm, C., Habraken, Y., Sung, P., Prakash, L., and Prakash, S. (1996) J. Biol. Chem. 271, 27987-27990
28. Burgers, P. M. J., and Yoder, B. L. (1993) J. Biol. Chem. 268, 19923-19926
29. Podust, V. N., Tiwari, N., Stephen, S., and Fanning, E. (1998) J. Biol. Chem. 273, 31992-31999
30. Krishna, T. S. R., Kong, X.-P., Gary, S., Burgers, P. M., and Kuriyan, J. (1994) Cell 79, 1233-1243
31. Tom, S., Henricksen, L. A., and Bambara, R. A. (2000) J. Biol. Chem. 275, 10498-10505
32. Warbrick, E., Lane, D. P., Glover, D. M., and Cox, L. S. (1997) Oncogene 14, 2313-2321
33. Jónsson, Z. O., Hindges, R., and Hübscher, U. (1998) EMBO 17, 2412-2425
34. Qiu, J., Qian, Y., Frank, P., Wintersberger, U., and Shen, B. (1999) Mol. Cell. Biol. 19, 8361-8371
35. Rumbaugh, J. A., Murante, R. S., Shi, S., and Bambara, R. A. (1997) J. Biol. Chem. 271, 22591-22599
36. Gary, R., Kim, K., Cornelius, H. L., Park, M. S., and Matsumoto, Y. (1999) J. Biol. Chem. 274, 4354-4363
37. Kim, K., Biade, S., and Matsumoto, Y. (1998) J. Biol. Chem. 273, 8842-8848
38. Klungland, A., and Lindahl, T. (1997) EMBO J. 16, 3341-3348
39. Kokoska, R. J., Stefanovic, L., Buermeyer, A. B., Liskay, R. M., and Petes, T. D. (1999) Genetics 151, 511-519
40. Tishkoff, D. X., Filosi, N., Gaida, G. M., and Kolodner, R. D. (1997) Cell 88, 253-263
41. Nolan, J. P., Shen, B., Park, M. S., and Sklar, L. A. (1996) Biochemistry 36, 11668-11676
42. Frank, G., Qiu, J., Somsouk, M., Weng, Y., Somsouk, L., Nolan, J. P., and Shen, B. (1998) J. Biol. Chem. 273, 33064-33072
43. Stucki, M., Jónsson, Z. O., and Hübscher, U. (2001) J. Biol. Chem. 276, 7843-7849
44. Gary, R., Park, M. S., Nolan, J. P., Cornelius, H. L., Kozyreva, O. G., Tran, H. T., Lobachev, K. S., Resnick, M. A., and Gordenin, D. A. (1999) Mol. Cell. Biol. 19, 5373-5382
45. Greene, A. L., Snipe, J. R., Gordenin, D. A., and Resnick, M. A. (1999) Hum. Mol. Genet. 8, 2263-2273
46. Levin, D. S., Bai, W., Yao, N., O'Donnell, M., and Tomkinson, A. E. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12863-12868
47. Montecucco, A., Rossi, R., Levin, D. S., Gary, R., Park, M. S., Motycka, T. A., Ciarrocchi, G., Villa, A., Biamonti, G., and Tomkinson, A. E. (1998) EMBO J. 17, 3786-3795
48. Gomes, X. V., and Burgers, P. M. J. (2000) EMBO 19, 3811-3821


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
L. Zheng, H. Dai, J. Qiu, Q. Huang, and B. Shen
Disruption of the FEN-1/PCNA Interaction Results in DNA Replication Defects, Pulmonary Hypoplasia, Pancytopenia, and Newborn Lethality in Mice
Mol. Cell. Biol., April 15, 2007; 27(8): 3176 - 3186.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Singh, L. Zheng, V. Chavez, J. Qiu, and B. Shen
Concerted Action of Exonuclease and Gap-dependent Endonuclease Activities of FEN-1 Contributes to the Resolution of Triplet Repeat Sequences (CTG)n- and (GAA)n-derived Secondary Structures Formed during Maturation of Okazaki Fragments
J. Biol. Chem., February 9, 2007; 282(6): 3465 - 3477.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
O. Mortusewicz, U. Rothbauer, M. C. Cardoso, and H. Leonhardt
Differential recruitment of DNA Ligase I and III to DNA repair sites
Nucleic Acids Res., July 19, 2006; 34(12): 3523 - 3532.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. Sporbert, P. Domaing, H. Leonhardt, and M. C. Cardoso
PCNA acts as a stationary loading platform for transiently interacting Okazaki fragment maturation proteins
Nucleic Acids Res., June 21, 2005; 33(11): 3521 - 3528.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Qiu, R. Liu, B. R. Chapados, M. Sherman, J. A. Tainer, and B. Shen
Interaction Interface of Human Flap Endonuclease-1 with Its DNA Substrates
J. Biol. Chem., June 4, 2004; 279(23): 24394 - 24402.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. Spiro and C. T. McMurray
Nuclease-Deficient FEN-1 Blocks Rad51/BRCA1-Mediated Repair and Causes Trinucleotide Repeat Instability
Mol. Cell. Biol., September 1, 2003; 23(17): 6063 - 6074.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
P. J. Lau, H. Flores-Rozas, and R. D. Kolodner
Isolation and Characterization of New Proliferating Cell Nuclear Antigen (POL30) Mutator Mutants That Are Defective in DNA Mismatch Repair
Mol. Cell. Biol., October 1, 2002; 22(19): 6669 - 6680.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Qiu, D. N. Bimston, A. Partikian, and B. Shen
Arginine Residues 47 and 70 of Human Flap Endonuclease-1 Are Involved in DNA Substrate Interactions and Cleavage Site Determination
J. Biol. Chem., June 28, 2002; 277(27): 24659 - 24666.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Dua, D. L. Levy, C. M. Li, P. M. Snow, and J. L. Campbell
In Vivo Reconstitution of Saccharomyces cerevisiae DNA Polymerase epsilon in Insect Cells. PURIFICATION AND CHARACTERIZATION
J. Biol. Chem., March 1, 2002; 277(10): 7889 - 7896.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Shibata and T. Nakamura
Defective Flap Endonuclease 1 Activity in Mammalian Cells Is Associated with Impaired DNA Repair and Prolonged S Phase Delay
J. Biol. Chem., January 4, 2002; 277(1): 746 - 754.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/39/36295    most recent
M103397200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map